Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region.

Related Articles Sex-based differences in the incidence of inflammatory bowel diseases-pooled analysis of population-based studies from the Asia-Pacific region. Aliment Pharmacol Ther. 2019 Feb 17;: Authors: Shah SC, Khalili H, Chen CY, Ahn HS, Ng SC, Burisch J, Colombel JF Abstract BACKGROUND: There appear to be differences in risk factor profiles for IBD between Asia-Pacific and Western populations, which might suggest idiosyncrasies in pathogenesis. Recently, sex-based differences in IBD according to the age of diagnosis have been described in Western populations. AIM: Our primary aim was to identify whether sex-based…

Read More

Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.

Related Articles Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019 Feb 17;: Authors: Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN Abstract BACKGROUND: The older patient group with inflammatory bowel diseases (IBD) is particularly vulnerable to consequences of disease and therapy-related side effects but little is known about the best treatment options in this population. AIM: To compare safety…

Read More

Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation.

Related Articles Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment Pharmacol Ther. 2019 Feb 10;: Authors: Steenstraten IC, Sebib Korkmaz K, Trivedi PJ, Inderson A, van Hoek B, Rodriguez Girondo MDM, Maljaars PWJ Abstract BACKGROUND: After liver transplantation primary sclerosing cholangitis (PSC), the condition returns in the transplanted liver in a subset of patients (recurrent primary sclerosing cholangitis, rPSC). AIM: To define risk factors for rPSC. METHODS: We searched Pubmed, Embase, Web of Science, and Cochrane library for articles published until March 2018.…

Read More

Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease.

Systematic review and meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 08;: Authors: Shah A, Morrison M, Burger D, Martin N, Rich J, Jones M, Koloski N, Walker MM, Talley NJ, Holtmann GJ Abstract BACKGROUND: Current data on small intestinal bacterial overgrowth (SIBO) in patients with inflammatory bowel diseases (IBD) are controversial. AIM: To conduct a systematic review and meta-analysis to determine the prevalence of SIBO in patients with ulcerative colitis (UC) and Crohn’s disease (CD). METHODS: Electronic databases were searched…

Read More

Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease.

Related Articles Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 07;: Authors: Chen P, Li Y, Li L, Yu Q, Chao K, Zhou G, Qiu Y, Feng R, Huang S, He Y, Chen B, Chen M, Zeng Z, Zhang S Abstract BACKGROUND: Owing to the importance of early treatment, simple and reliable methods for monitoring inflammatory bowel disease (IBD) are needed. AIMS: To determine whether circulating microRNAs are reliable biomarkers for IBD monitoring. METHODS: Serum levels of…

Read More

Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.

Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb 08;: Authors: Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, Ghosh S, Bhala N Abstract BACKGROUND: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients.…

Read More

Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.

Related Articles Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther. 2019 Jan 31;: Authors: Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA Abstract BACKGROUND: Evaluation of the metabolomic profile of patients with irritable bowel syndrome offers an opportunity to identify novel pathophysiological targets and biomarkers that could discriminate this disorder from related conditions. AIM: To identify potential urinary…

Read More

Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study.

Related Articles Trends in the epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based study. Aliment Pharmacol Ther. 2019 Jan 27;: Authors: Ghersin I, Khteeb N, Katz LH, Daher S, Shamir R, Assa A Abstract BACKGROUND: The incidence and prevalence trends of inflammatory bowel disease (IBD) vary between developed and developing countries. AIM: To investigate the prevalence and associated sociodemographic factors of IBD in Israeli Jewish adolescents METHODS: The files of the army medical corps were reviewed for adolescents recruited in 2002-2016 with confirmed IBD. Covariate data included…

Read More

Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.

Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Feb;49(4):476-477 Authors: Ahmed T, Brown F, Ahmed R, Shah A, Whitehead S, Steed H, Brookes MJ PMID: 30689253 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30689253?dopt=Abstract

Read More

Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease – authors’ reply.

Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease – authors’ reply. Aliment Pharmacol Ther. 2019 Feb;49(4):477-478 Authors: de Francisco R, Castaño-García A, Riestra S PMID: 30689254 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30689254?dopt=Abstract

Read More
<< Go Back